Navigation Links
Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
Date:4/29/2008

s for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to the preclinical data and plans and potential efficacy of R788. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "may," "can," "support," "indicate," "potential," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates, potential problems that may arise in the clinical testing and approval process and Rigel's need for additional capital, as well as other risks detailed from time to time in Rigel's SEC reports, including its Form 10-K for the year ended December 31, 2007. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: rrodriguez@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
3. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
4. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
9. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
10. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
11. Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Boston Scientific Corporation (NYSE: ... the annual EuroPCR Scientific Program May 21-24 in ... to present a particularly rich and diversified set of ... Dawkins , M.D., global chief medical officer, Boston ... be presented, including the NG PROMUS trial, which evaluated ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
(Date:5/16/2013)... and SYDNEY , May 16, 2013 /PRNewswire/ ... HIN), a leading innovator of less invasive, miniaturized circulatory support ... today announced that CEO Doug Godshall ... Conference at 11:00 a.m. EDT on Monday, May 20, 2013.  ... Sheraton New York Hotel. A live webcast of ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... biotechnology company,developing clinical stage treatments for cancer and ... from its Phase II,clinical trial of OncoVEX GM-CSF, ... at the 2008 Annual Meeting of the American,Society ... Clinical Trial Details, Phase II Trial Design: ...
... May 31 Millennium Pharmaceuticals, The Takeda,Oncology Company, ... trials of VELCADE based therapies that showed consistently ... diagnosed multiple,myeloma (MM). CR is one of the ... selected for oral presentation at the American Society,of ...
Cached Medicine Technology:BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 6Webs.com ... The simple to read reviews and comprehensive comparisons make ... impartial home security reviews. 6Webs.com just recently finished conducting ... system providers. , Tim Smythe from 6Webs.com reports, "There ... systems due to their ease of use, expandability and ...
(Date:5/18/2013)... Mexico, DF (PRWEB) May 18, 2013 ... by leading ayurvedic education institution in the West. Program ... Learning education. , Ayurveda is a healing modality practiced ... Ayurvedica ), it is considered that health begins when ... a profound understanding of their individual needs. Ayurveda aims ...
(Date:5/18/2013)... IL (PRWEB) May 18, 2013 The ... Oregon Gov. John A. Kitzhaber, M.D., (D) to sign ... law by prohibiting minors under the age of 18 ... would become the third state in the nation to ... have enacted similar indoor tanning bans for minors. Nationwide, ...
(Date:5/18/2013)... Ohio (PRWEB) May 18, 2013 ... Annual Conference, on May 17-22 in Austin, TX ... gather for educational and networking opportunities. , ... brushes, flexible scope repair capabilities and ... with valuable educational information on proper instrument care ...
(Date:5/18/2013)... John Ravera, D.D.S., a Newport Beach ... new member to his dental team, Courtney Marino. , Marino ... for over 10 years. She received her degree from West ... a member of Sigma Pi Alpha, a national honor society ... with patients of all ages, helping them understand the importance ...
Breaking Medicine News(10 mins):Health News:Best Wireless Home Security System Companies Released by 6Webs.com 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2
... babies for the presence of a common infection was approved ... streptococcus// is a common infection that is passed from mother ... or even death. ,Although all women are tested ... leave some babies at risk for contracting an infection from ...
... certain premature babies to inhale small amounts of nitric ... bronchopulmonary dysplasia, according// to the results of two studies ... born with this condition each year in the United ... are too immature to mix inhaled air properly with ...
... considering becoming pregnant could prevent preeclampsia if they started ... following it up// during the first three months of ... blood pressure shoots up dangerously and could prove lethal ... of Pittsburgh say that this condition could be avoided ...
... the cornerstones of managing type 2 diabetes. But few ... ,Now, a new systematic review shows that exercise ... sensitivity to insulin, and decreases blood lipids (fats) while ... 2 diabetes is an increasing problem in Western societies ...
... of Medicine, University of California, Los Angels and Valencia, ... developed an alternative to the conventional epilepsy treatment. ... study and the clinical trails show that it has ... nerve that prevents seizures is stimulated to inhibit epilepsy. ...
... by Linda Chaudron, M.D., an assistant professor of psychiatry, pediatrics ... is a disorder which is fast rising among new mothers. ... screened for a period of 12 months after childbirth. Such ... as the symptoms, develop throughout the year. Only if ...
Cached Medicine News:Health News:FDA Approves New Test For Screening Infection In Babies 2Health News:FDA Approves New Test For Screening Infection In Babies 3Health News:Nitric Oxide Could Benefit Premature Babies 2Health News:Using Multivitamins Before And After Conception Averts Preeclampsia 2Health News:Using Multivitamins Before And After Conception Averts Preeclampsia 3Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3Health News:Alternative to the Conventional Seizure Treatment 2Health News:Early Diagnosis of Postpartum Depression Is Very Essential Among New Mothers 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,409-7) or contact custom...
... samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, ... Volume Range (ul) ... 1.0~1.5 Imprecision(%) ... 10 ...
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Medicine Products: